You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

280 Results
Drug
Other Name(s): Nubeqa®
Feb 2026
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    darolutamide - For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC), based on criteria
Exceptional Access Program
    darolutamide - For the treatment of metastatic castration-sensitive prostate cancer (mCSPC), based on criteria
Feb 2026
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Palliative
Feb 2026
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Feb 2026
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Palliative
Feb 2026
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Feb 2026
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Feb 2026
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Feb 2026
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Feb 2026
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Platinum and Pemetrexed for First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Updated
Feb 2026
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Platinum and Pemetrexed for First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Feb 2026
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
Exceptional Access Program
    zanubrutinib - For the treatment of relapsed or refractory Waldenström Macroglobulinemia, according to clinical criteria
Feb 2026

Pages